<DOC>
	<DOCNO>NCT00002097</DOCNO>
	<brief_summary>To evaluate clinical toxicity , safety , maximum tolerate dose ( MTD ) intravenous nystatin patient HIV infection . To evaluate potential anti-HIV activity clinical pharmacology intravenous nystatin .</brief_summary>
	<brief_title>A Phase I/II Clinical Study Nystatin I.V . ( Intravenous ) Patients With HIV Infection .</brief_title>
	<detailed_description>Cohorts three patient treat escalate dos intravenous nystatin , administer every day , MTD reach . Each cohort observe toxicity least 2 week escalation subsequent patient cohort initiate .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Nystatin</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Required : Aerosolized pentamidine ( 300 mg month ) PCP prophylaxis patient CD4 count &lt; = 200 cells/mm3 . ( Patients CD4 count &gt; 200 cells/mm3 already aerosolize pentamidine may continue therapy discretion investigator . ) Allowed : Prophylaxis Mycobacterium avium Complex patient CD4 count &lt; = 100 cells/mm3 . Concurrent Treatment : Allowed : Local treatment Kaposi 's sarcoma lesion less 25 percent increase measurable disease . Patients must : HIV antibody positivity . Absolute CD4 count &lt; 500 cells/mm3 two determination within 15 day prior study entry . At least 6 month prior zidovudine ( AZT ) therapy . No active opportunistic infection require ongoing therapy . Normal neurologic status standard assessment . Life expectancy least 6 month . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Neoplasm basal cell carcinoma skin stable untreated HIVrelated Kaposi 's sarcoma ( provide progression Kaposi 's sarcoma beyond 25 percent measurable disease ) . Clinically significant cardiac disease . Known hypersensitivity polyene antibiotic . Patients follow prior condition exclude : History myocardial infarction arrhythmia . Prior Medication : Excluded within 2 week prior study entry : Antiretroviral agent interferon . Biological response modifier . Corticosteroids . Cytotoxic chemotherapeutic agent . Drugs cause neutropenia significant nephrotoxicity . Rifampin rifampin derivative . Systemic antiinfectives . Prior Treatment : Excluded within 2 week prior study entry : Radiation therapy . Active drug alcohol abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 1994</verification_date>
	<keyword>Nystatin</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
</DOC>